1
|
Illarionova V, Rogova A, Tuchynskaya K, Volok V, Rogova Y, Baryshnikova V, Turchenko Y, Litov A, Kalyanova A, Siniugina A, Ishmukhametov A, Karganova G. Inapparent Tick-Borne Orthoflavivirus Infection in Macaca fascicularis: A Model for Antiviral Drug and Vaccine Research. Vaccines (Basel) 2023; 11:1754. [PMID: 38140159 PMCID: PMC10747564 DOI: 10.3390/vaccines11121754] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2023] [Revised: 11/17/2023] [Accepted: 11/23/2023] [Indexed: 12/24/2023] Open
Abstract
Tick-borne encephalitis virus (TBEV) and Powassan virus (POWV) are neurotropic tick-borne orthoflaviviruses. They cause mostly asymptomatic infections in hosts, but severe forms with CNS involvement can occur. Studying the early stages of viral infections in humans is challenging, and appropriate animal models are essential for understanding the factors determining the disease severity and for developing emergency prophylaxis and treatment options. In this work, we assessed the model of the early stages of TBEV and POWV mono- and co-infections in Macaca fascicularis. Serological, biochemical, and virological parameters were investigated to describe the infection, including its impact on animal behavior. Viremia, neutralizing antibody dynamics, and viral load in organs were chosen as the main parameters distinguishing early-stage orthoflavivirus infection. Levels of IFNα, monocyte count, and cognitive test scores were proposed as additional informative indicators. An assessment of a tick-borne encephalitis vaccine using this model showed that it provided partial protection against POWV infection in Macaca fascicularis without signs of antibody-dependent enhancement of infection.
Collapse
Affiliation(s)
- Victoria Illarionova
- FSASI “Chumakov FSC R&D IBP RAS” (Institute of Poliomyelitis), Laboratory of Biology of Arbovirus, Moscow 108819, Russia; (V.I.); (A.R.); (K.T.); (V.V.); (Y.R.); (A.L.); (A.K.)
- Department of Biology, Lomonosov Moscow State University, Leninskie Gory 1 bd. 3, Moscow 119991, Russia
| | - Anastasia Rogova
- FSASI “Chumakov FSC R&D IBP RAS” (Institute of Poliomyelitis), Laboratory of Biology of Arbovirus, Moscow 108819, Russia; (V.I.); (A.R.); (K.T.); (V.V.); (Y.R.); (A.L.); (A.K.)
| | - Ksenia Tuchynskaya
- FSASI “Chumakov FSC R&D IBP RAS” (Institute of Poliomyelitis), Laboratory of Biology of Arbovirus, Moscow 108819, Russia; (V.I.); (A.R.); (K.T.); (V.V.); (Y.R.); (A.L.); (A.K.)
| | - Viktor Volok
- FSASI “Chumakov FSC R&D IBP RAS” (Institute of Poliomyelitis), Laboratory of Biology of Arbovirus, Moscow 108819, Russia; (V.I.); (A.R.); (K.T.); (V.V.); (Y.R.); (A.L.); (A.K.)
- Research Institute for Systems Biology and Medicine (RISBM), Laboratory of Infectious Immunology, Moscow 117246, Russia
| | - Yulia Rogova
- FSASI “Chumakov FSC R&D IBP RAS” (Institute of Poliomyelitis), Laboratory of Biology of Arbovirus, Moscow 108819, Russia; (V.I.); (A.R.); (K.T.); (V.V.); (Y.R.); (A.L.); (A.K.)
| | - Victoria Baryshnikova
- FSASI “Chumakov FSC R&D IBP RAS” (Institute of Poliomyelitis), Laboratory of Biochemistry, Moscow 108819, Russia; (V.B.); (Y.T.)
| | - Yuriy Turchenko
- FSASI “Chumakov FSC R&D IBP RAS” (Institute of Poliomyelitis), Laboratory of Biochemistry, Moscow 108819, Russia; (V.B.); (Y.T.)
| | - Alexander Litov
- FSASI “Chumakov FSC R&D IBP RAS” (Institute of Poliomyelitis), Laboratory of Biology of Arbovirus, Moscow 108819, Russia; (V.I.); (A.R.); (K.T.); (V.V.); (Y.R.); (A.L.); (A.K.)
- Institute of Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University, Moscow 119991, Russia;
| | - Anna Kalyanova
- FSASI “Chumakov FSC R&D IBP RAS” (Institute of Poliomyelitis), Laboratory of Biology of Arbovirus, Moscow 108819, Russia; (V.I.); (A.R.); (K.T.); (V.V.); (Y.R.); (A.L.); (A.K.)
| | - Alexandra Siniugina
- FSASI “Chumakov FSC R&D IBP RAS” (Institute of Poliomyelitis), Moscow 108819, Russia;
| | - Aydar Ishmukhametov
- Institute of Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University, Moscow 119991, Russia;
- FSASI “Chumakov FSC R&D IBP RAS” (Institute of Poliomyelitis), Moscow 108819, Russia;
| | - Galina Karganova
- FSASI “Chumakov FSC R&D IBP RAS” (Institute of Poliomyelitis), Laboratory of Biology of Arbovirus, Moscow 108819, Russia; (V.I.); (A.R.); (K.T.); (V.V.); (Y.R.); (A.L.); (A.K.)
- Institute of Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University, Moscow 119991, Russia;
| |
Collapse
|
2
|
Baryshnikova V, Turchenko Y, Tuchynskaya K, Belyaletdinova I, Butenko A, Dereventsova A, Ignatiev G, Kholodilov I, Larichev V, Lyapeykova E, Rogova A, Shakaryan A, Shishova A, Gmyl A, Karganova G. Recombinant TBEV Protein E of the Siberian Subtype Is a Candidate Antigen in the ELISA Test System for Differential Diagnosis. Diagnostics (Basel) 2023; 13:3277. [PMID: 37892100 PMCID: PMC10606673 DOI: 10.3390/diagnostics13203277] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2023] [Revised: 08/01/2023] [Accepted: 10/18/2023] [Indexed: 10/29/2023] Open
Abstract
The tick-borne encephalitis virus (TBEV) is one of the most common members of the Orthoflavivirus genus, which comprises the causative agents of severe diseases in humans and animals. Due to the expanding areas of orthoflavivirus infection, its differential diagnosis is highly demanded. Commercial test kits based on inactivated TBEV may not provide reliable differentiation between flaviviruses because of serological crossover in this genus. Application of recombinant domains (sE and dIII) of the TBEV Sukhar-strain protein E as antigens in an ELISA test system allowed us to identify a wide range of antibodies specific to different TBEV strains. We tested 53 sera from human patients with confirmed TBE diagnosis (the efficacy of our test system based on sE protein was 98%) and 56 sera from patients with other orthoflavivirus infections in which no positive ones were detected using our ELISA test system, thus being indicative of its 100% specificity. We also tested mouse and rabbit sera containing antibodies specific to 17 TBEV strains belonging to different subtypes; this assay exhibited high efficacy and differentiation ability in detecting antibodies against TBEV from other orthoflaviviruses such as Omsk hemorrhagic fever, Powassan, yellow fever, dengue, West Nile, Zika, and Japanese encephalitis viruses.
Collapse
Affiliation(s)
- Victoria Baryshnikova
- FSASI “Chumakov FSC R&D IBP RAS” (Institute of Poliomyelitis), Moscow 108819, Russia (Y.T.); (I.B.); (A.S.); (A.S.)
| | - Yuriy Turchenko
- FSASI “Chumakov FSC R&D IBP RAS” (Institute of Poliomyelitis), Moscow 108819, Russia (Y.T.); (I.B.); (A.S.); (A.S.)
| | - Ksenia Tuchynskaya
- FSASI “Chumakov FSC R&D IBP RAS” (Institute of Poliomyelitis), Moscow 108819, Russia (Y.T.); (I.B.); (A.S.); (A.S.)
| | - Ilmira Belyaletdinova
- FSASI “Chumakov FSC R&D IBP RAS” (Institute of Poliomyelitis), Moscow 108819, Russia (Y.T.); (I.B.); (A.S.); (A.S.)
| | - Alexander Butenko
- D.I. Ivanovsky Institute of Virology Division of N.F. Gamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation, Moscow 123098, Russia
| | - Alena Dereventsova
- FSASI “Chumakov FSC R&D IBP RAS” (Institute of Poliomyelitis), Moscow 108819, Russia (Y.T.); (I.B.); (A.S.); (A.S.)
| | - Georgy Ignatiev
- FSASI “Chumakov FSC R&D IBP RAS” (Institute of Poliomyelitis), Moscow 108819, Russia (Y.T.); (I.B.); (A.S.); (A.S.)
| | - Ivan Kholodilov
- FSASI “Chumakov FSC R&D IBP RAS” (Institute of Poliomyelitis), Moscow 108819, Russia (Y.T.); (I.B.); (A.S.); (A.S.)
| | - Victor Larichev
- D.I. Ivanovsky Institute of Virology Division of N.F. Gamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation, Moscow 123098, Russia
| | - Ekaterina Lyapeykova
- Infectious Clinical Hospital No. 1 of the Moscow City Health Department, Moscow 125310, Russia;
| | - Anastasiya Rogova
- FSASI “Chumakov FSC R&D IBP RAS” (Institute of Poliomyelitis), Moscow 108819, Russia (Y.T.); (I.B.); (A.S.); (A.S.)
| | - Armen Shakaryan
- FSASI “Chumakov FSC R&D IBP RAS” (Institute of Poliomyelitis), Moscow 108819, Russia (Y.T.); (I.B.); (A.S.); (A.S.)
- Department of Infectious Diseases in Children, Faculty of Pediatrics, Pirogov Russian National Research Medical University, Moscow 117997, Russia
| | - Anna Shishova
- FSASI “Chumakov FSC R&D IBP RAS” (Institute of Poliomyelitis), Moscow 108819, Russia (Y.T.); (I.B.); (A.S.); (A.S.)
- Institute of Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University, Moscow 119991, Russia
| | - Anatoly Gmyl
- FSASI “Chumakov FSC R&D IBP RAS” (Institute of Poliomyelitis), Moscow 108819, Russia (Y.T.); (I.B.); (A.S.); (A.S.)
| | - Galina Karganova
- FSASI “Chumakov FSC R&D IBP RAS” (Institute of Poliomyelitis), Moscow 108819, Russia (Y.T.); (I.B.); (A.S.); (A.S.)
- Institute of Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University, Moscow 119991, Russia
| |
Collapse
|
3
|
Tuchynskaya K, Volok V, Illarionova V, Okhezin E, Polienko A, Belova O, Rogova A, Chernokhaeva L, Karganova G. Experimental Assessment of Possible Factors Associated with Tick-Borne Encephalitis Vaccine Failure. Microorganisms 2021; 9:1172. [PMID: 34072340 PMCID: PMC8229799 DOI: 10.3390/microorganisms9061172] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2021] [Revised: 05/26/2021] [Accepted: 05/27/2021] [Indexed: 12/30/2022] Open
Abstract
Currently the only effective measure against tick-borne encephalitis (TBE) is vaccination. Despite the high efficacy of approved vaccines against TBE, rare cases of vaccine failures are well documented. Both host- and virus-related factors can account for such failures. In this work, we studied the influence of mouse strain and sex and the effects of cyclophosphamide-induced immunosuppression on the efficacy of an inactivated TBE vaccine. We also investigated how an increased proportion of non-infectious particles in the challenge TBE virus would affect the protectivity of the vaccine. The vaccine efficacy was assessed by mortality, morbidity, levels of viral RNA in the brain of surviving mice, and neutralizing antibody (NAb) titers against the vaccine strain and the challenge virus. Two-dose vaccination protected most animals against TBE symptoms and death, and protectivity depended on strain and sex of mice. Immunosuppression decreased the vaccine efficacy in a dose-dependent manner and changed the vaccine-induced NAb spectrum. The vaccination protected mice against TBE virus neuroinvasion and persistence. However, viral RNA was detected in the brain of some asymptomatic animals at 21 and 42 dpi. Challenge with TBE virus enriched with non-infectious particles led to lower NAb titers in vaccinated mice after the challenge but did not affect the protective efficacy.
Collapse
Affiliation(s)
- Ksenia Tuchynskaya
- FSBSI “Chumakov FSC R&D IBP RAS”, 108819 Moscow, Russia; (K.T.); (V.V.); (V.I.); (E.O.); (A.P.); (O.B.); (A.R.); (L.C.)
| | - Viktor Volok
- FSBSI “Chumakov FSC R&D IBP RAS”, 108819 Moscow, Russia; (K.T.); (V.V.); (V.I.); (E.O.); (A.P.); (O.B.); (A.R.); (L.C.)
- Department of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia
| | - Victoria Illarionova
- FSBSI “Chumakov FSC R&D IBP RAS”, 108819 Moscow, Russia; (K.T.); (V.V.); (V.I.); (E.O.); (A.P.); (O.B.); (A.R.); (L.C.)
- Department of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia
| | - Egor Okhezin
- FSBSI “Chumakov FSC R&D IBP RAS”, 108819 Moscow, Russia; (K.T.); (V.V.); (V.I.); (E.O.); (A.P.); (O.B.); (A.R.); (L.C.)
- Department of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia
| | - Alexandra Polienko
- FSBSI “Chumakov FSC R&D IBP RAS”, 108819 Moscow, Russia; (K.T.); (V.V.); (V.I.); (E.O.); (A.P.); (O.B.); (A.R.); (L.C.)
| | - Oxana Belova
- FSBSI “Chumakov FSC R&D IBP RAS”, 108819 Moscow, Russia; (K.T.); (V.V.); (V.I.); (E.O.); (A.P.); (O.B.); (A.R.); (L.C.)
| | - Anastasia Rogova
- FSBSI “Chumakov FSC R&D IBP RAS”, 108819 Moscow, Russia; (K.T.); (V.V.); (V.I.); (E.O.); (A.P.); (O.B.); (A.R.); (L.C.)
| | - Liubov Chernokhaeva
- FSBSI “Chumakov FSC R&D IBP RAS”, 108819 Moscow, Russia; (K.T.); (V.V.); (V.I.); (E.O.); (A.P.); (O.B.); (A.R.); (L.C.)
| | - Galina Karganova
- FSBSI “Chumakov FSC R&D IBP RAS”, 108819 Moscow, Russia; (K.T.); (V.V.); (V.I.); (E.O.); (A.P.); (O.B.); (A.R.); (L.C.)
- Department of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia
- Institute of Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University, 119991 Moscow, Russia
| |
Collapse
|